Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication

Jean Jacques Parienti, Kathleen Ragland, Frédéric Lucht, Blanchardière De La Arnaud, Sylvie Dargàre, Yazdan Yazdanpanah, Jean Jacques Dutheil, Philippe Perré, Renaud Verdón, David R. Bangsberg

Research output: Contribution to journalArticlepeer-review

59 Scopus citations

Abstract

Consecutive missed doses may differentially impact the efficacy of antiretroviral therapy associated with the use of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) and a ritonavir-boosted protease inhibitor (PI). In a cohort of 72 subjects receiving a boosted PI, average adherence to dosage was a better predictor of human immunodeficiency virus (HIV) replication than was the duration or frequency of treatment interruption. In contrast with an NNRTI, consecutive missed doses of a boosted PI did not emerge as a major risk factor for HIV replication

Original languageEnglish (US)
Pages (from-to)1192-1197
Number of pages6
JournalClinical Infectious Diseases
Volume50
Issue number8
DOIs
StatePublished - Apr 15 2010

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication'. Together they form a unique fingerprint.

Cite this